Following U.S., Japan Grants Eisai Breast Cancer Drug Priority Review Status
This article was originally published in PharmAsia News
Executive Summary
The Ministry of Health, Labor and Welfare June 23 designated a priority review for Eisai's eribulin being developed for breast cancer